Home・Lista de Ações・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Fechado

SetorSaúde

58.79 1.75

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

58.41

Máximo

58.99

Indicadores-chave
By Trading Economics
Rendimento	-34M 106M
Vendas	-108M 766M
P/E Médio do Setor	41.234 56.269
EPS	0.76
Margem de lucro	13.773
Funcionários	3,221
EBITDA	177M 173M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+47.48% upside

Dividendos
By Acuity
Próximos Ganhos	3 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	679M 11B
Abertura anterior	57.04
Fecho anterior	58.79

Sentimento de Notícias

By Acuity

34%

66%

89 / 342 Ranking em Healthcare

BioMarin Pharmaceutical Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de jul. de 2026, 22:51 UTC

Biomarin Pharmaceutical Inc. shares were roughly flat in after-market trading, with no specific news identified. The stock has shown little change since Thursday's close.

1 de jul. de 2026, 19:36 UTC

Biomarin Pharmaceutical Inc's shares are higher today, reaching a notable intraday high amid broader market caution and no specific company news identified.

30 de jun. de 2026, 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

29 de jun. de 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, retracing from earlier gains amid mixed U.S. equity performance and broader inflation concerns.

26 de jun. de 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 de jun. de 2026, 23:31 UTC

Biomarin Pharmaceutical shares declined in after-market trading, despite remaining above the 20-day moving average and near the upper end of its one-month range.

24 de jun. de 2026, 19:41 UTC

Biomarin Pharmaceutical Inc is gaining Wednesday, supported by strong momentum in the Biotechnology sub-sector, despite an earlier decline in the session.

23 de jun. de 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. Broader market sentiment is affected by declines in Asian markets amid tech sector concerns.

22 de jun. de 2026, 23:56 UTC

Biomarin Pharmaceutical shares showed little change in after-market trading. The stock remains within the middle of its one-month trading range.

19 de jun. de 2026, 00:01 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market hours, recovering from earlier lows and reflecting strong performance since Thursday's close.

18 de jun. de 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close despite earlier fluctuations in the session.

17 de jun. de 2026, 20:08 UTC

Event

Biomarin Pharmaceutical is trading lower amid broader market declines, despite presenting new data on VOXZOGO® and BMN 333 at the ENDO 2026 conference.

16 de jun. de 2026, 23:41 UTC

Event

Biomarin Pharmaceutical presented new data on investigational therapies at the Endocrine Society Annual Meeting. Shares showed little change during after-market hours.

15 de jun. de 2026, 13:26 UTC

Biomarin Pharmaceutical Inc is trading higher in pre-market hours, reflecting positive momentum amid a broader upward trend in Asian markets, including a surge in the Nikkei Index.

13 de jun. de 2026, 00:01 UTC

Biomarin Pharmaceutical Inc shares declined in after-market trading, retracing from earlier gains while remaining above the 20-day moving average. No specific news was identified.

12 de jun. de 2026, 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

11 de jun. de 2026, 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, reaching an early session low. Broader economic news includes an unexpected rise in initial jobless claims.

10 de jun. de 2026, 20:03 UTC

Biomarin Pharmaceutical shares are lower today, reflecting broader market trends amid volatility. The stock peaked earlier in the session before declining significantly.

9 de jun. de 2026, 20:03 UTC

Biomarin Pharmaceutical Inc shares are higher, reaching a session high and trading above its 20-day moving average. No specific news was identified for the move.

8 de jun. de 2026, 22:51 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, reflecting a notable decline despite a broader rebound in US stocks, particularly in the semiconductor sector.

5 de jun. de 2026, 20:07 UTC

Biomarin Pharmaceutical Inc shares are modestly higher, reflecting broader market gains amid robust job growth data. No specific company news was identified.

4 de jun. de 2026, 22:31 UTC

Biomarin Pharmaceutical Inc is trading lower in after-market hours amid a broader market decline and rising U.S. Treasury yields impacting biotechnology stocks.

3 de jun. de 2026, 20:06 UTC

Biomarin Pharmaceutical shares are higher amid broader market strength following a positive ADP Employment Report, which showed job growth exceeding expectations.

2 de jun. de 2026, 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, continuing a decline since Monday. The stock closed at its lowest point after an early high.

1 de jun. de 2026, 23:03 UTC

Biomarin Pharmaceutical shares declined in after-market trading, continuing a downward trend since Monday's close, despite remaining above the 20-day moving average.

29 de mai. de 2026, 23:41 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid routine trading patterns.

28 de mai. de 2026, 22:36 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting notable movement since Thursday's close amid broader market dynamics and economic data.

27 de mai. de 2026, 19:41 UTC

Biomarin Pharmaceutical Inc shares are lower Wednesday, reversing recent gains. No specific news was identified to explain the decline since Tuesday's close.

26 de mai. de 2026, 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from a recent trend of higher closes amid rising bond yields and no specific company news.

Comparação entre Pares

Variação de preço

BioMarin Pharmaceutical Inc Previsão

Preço-alvo

By TipRanks

47.48% parte superior

Previsão para 12 meses

Média 87 USD 47.48%

Máximo 120 USD

Mínimo 50 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para BioMarin Pharmaceutical Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

Comprar

Manter

Vender

Com base em 20 analistas que deram avaliações de ações para BioMarin Pharmaceutical Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

89 / 342 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.